Pityriasis rosea following CoronaVac COVID‐19 vaccination: a case report

descriptionPublicationkeyboard_double_arrow_right Article 10 May 2021 Turkey English Publisher:WileyJournal:Journal of the European Academy of Dermatology and Venereology, volume 35 (issn: 0926-9959, eissn: 1468-3083,

Copyright policy )

Authors: E. Akdaş; N. İlter; B. Öğüt; Ö. Erdem;

doi: 10.1111/jdv.17316

Pityriasis rosea following CoronaVac COVID‐19 vaccination: a case report

- Summary
- Metrics

Abstract

According to official data published by the World Health Organization, more than 100 million cases worldwide have been confirmed to be infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), causing over two million deaths. The CoronaVac vaccine, an inactivated vaccine candidate against COVID-19 containing inactivated SARS-CoV-2, is a Chinese vaccine developed by Sinovac Life Sciences.

Country

Turkey

Related Organizations

Gazi University
Turkey
Department of Microbiology
United States
Hospital Universitario La Paz
Spain

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	24
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%